Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO Prophylaxis for CTIT in High Cardiac Risk Patients
NCT05411705Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human thrombopoietin in Thrombocytopenia (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Proportion of patients whose platelet count is >= 75x10^9/L. Started Jun 2022; status: recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT05411705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411705.